Semaglutide meaning: what the word tells you about how it works

Step 1, understanding what the name actually means

Pharmaceutical names follow a naming convention that groups medicines by their biological family. The -glutide suffix signals membership of the glucagon-like peptide-1 (GLP-1) receptor agonist class, medicines that bind to and activate the same receptor as your body's own GLP-1 hormone. Sema- distinguishes this particular molecule from others in the family, such as liraglutide or tirzepatide (which activates two receptors rather than one).

GLP-1 is released from cells in the small intestine within minutes of eating. Its jobs include prompting the pancreas to release insulin in response to glucose, slowing the rate at which the stomach empties into the small bowel, and signalling to the brain that you have eaten enough. Semaglutide is engineered to do the same things but to last much longer in the body than the natural hormone does, long enough to be effective as a once-weekly injection or a once-daily tablet. The NHS medicines page on semaglutide sets out how it works in plain language for patients.

Knowing the mechanism matters practically: most of semaglutide's common side effects (nausea, loose stools, indigestion) are a direct consequence of slowing gastric emptying. They are most noticeable in the first few weeks and typically settle as the body adjusts. That context makes them less alarming when they arrive.

Step 2, recognising semaglutide across its different brand names

The same molecule appears under several names in the UK, each licensed for a different purpose, and the distinction is not just administrative.

Wegovy (2.4 mg weekly injection, or 25 mg daily tablet as of June 2026) is licensed specifically for weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related health condition such as high blood pressure or type 2 diabetes. This is the form you will encounter at a weight-management service. The route to obtaining Wegovy legally in the UK is a prescription following clinical assessment, there is no other lawful path.

Ozempic is also semaglutide, but it is licensed for type 2 diabetes management, not weight loss. Prescribing it for weight loss is off-label and is not something regulated weight-management services do. The MHRA is clear on this distinction.

Rybelsus is the oral semaglutide tablet licensed for type 2 diabetes (at 3 mg, 7 mg and 14 mg doses), entirely separate from the Wegovy tablet for weight loss. The two products share an active ingredient but have different dose ladders, different absorption profiles and different licensed indications. If you have read about oral semaglutide for weight loss, the product being described is the Wegovy tablet, not Rybelsus.

Keeping these names straight saves confusion and helps you have a more productive conversation with a prescriber. You can read more about what Wegovy means and how the brand name came about.

Step 3, what the licensed evidence shows about semaglutide for weight loss

The weight-management evidence base for semaglutide comes primarily from the STEP clinical programme. STEP 1 (1,961 adults with obesity or overweight plus at least one weight-related condition, no diabetes, 68 weeks of treatment) found that participants taking 2.4 mg semaglutide weekly lost an average of around 15% of body weight compared with around 2.4% on placebo. NICE considered this evidence when recommending Wegovy in 2023 (guidance TA875), subject to use within a specialist weight management service and for a maximum of two years.

More recently, a higher 7.2 mg weekly dose was approved by the MHRA in early 2026, with trial data suggesting average weight loss approaching 20.7% over 72 weeks, narrowing the gap with tirzepatide at its highest dose. A dedicated single-dose 7.2 mg pen received approval on 14 April 2026. The higher-dose semaglutide options are discussed in detail separately; whether a particular strength is right for you is a clinical decision, not a self-selection one.

One practical detail worth knowing: semaglutide treatment starts at 0.25 mg weekly and is titrated gradually by the prescriber over several months, precisely because the dose that produces the most benefit also carries the highest risk of GI discomfort if introduced too quickly. The titration schedule is not optional and is not something to accelerate without clinical guidance. If you are curious about what stopping treatment involves, the process of coming off Wegovy is worth reading about before you start.

Step 4 (next steps if semaglutide sounds relevant to you

If you have reached this page because you are considering weight-management treatment, the practical next step is a clinical consultation) not a purchase decision. Semaglutide is a prescription-only medicine, which means a qualified prescriber must review your health history, current medicines and BMI before any prescription can be written. At our pharmacy, every consultation is read personally by a GPhC-registered Independent Prescriber; a real clinician reviews your answers on the same day, not software working through a queue.

A question our prescribers hear most weeks is whether someone has the 'right' BMI for treatment. The honest answer is that BMI is one factor, not the only one: the prescriber looks at the full picture, including any weight-related conditions and current medications. Lower thresholds apply for some ethnic backgrounds under UK guidance, which the prescriber will account for automatically. You can explore the weight-loss treatment overview for a broader sense of the options available, or review the frequently asked questions if something specific is on your mind.

The tablet before the kettle goes on. The weekly injection on a Sunday evening. Whatever form suits your life better is worth discussing openly, there is no single right answer, only the one that works for you. When you are ready to ask those questions, speaking to our prescribers is the right place to start.